Resmetirom for NASH with Liver Fibrosis
7
0
2024-4-1 17:41
Welcome Video from the Editors of NEJM Evidence
Drug-Eluting Scaffold for Infrapopliteal Disease
The Plight of Primary Care, Part 2
Understanding Heparin-Induced Thrombocytopenia (HIT)：Causes, pathophysiology, and Treatment
2023 Notable Articles | New England Journal of Medicine
Daratumumab Plus VRd for Multiple Myeloma
The Plight of Primary Care, Part 1
Type 2 Diabetes — Controlling the Epidemic (Episode 2 of 4) | NEJM
0 bullet chats
Please Sign In first
LikesSend-PenFavorites
Scan by WeChatUnauthorized reproduction is prohibited
Currently, no pharmacotherapies are approved for nonalcoholic steatohepatitis. Resmetirom is an oral, liver-directed, THR-β–selective agonist in development for NASH.
Comments 0
Please to post a comment~
Loading...
Related Suggestion